Differential effect of the GPIIb/IIIa antagonist orbofiban on human platelet aggregate formation in vitro
- 1 May 2003
- journal article
- Published by Elsevier in Thrombosis Research
- Vol. 110 (2-3) , 99-105
- https://doi.org/10.1016/s0049-3848(03)00337-2
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Randomized Trial of Aspirin, Sibrafiban, or Both for Secondary Prevention After Acute Coronary SyndromesCirculation, 2001
- Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa AntagonistsCirculation, 2001
- Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients With Unstable Coronary Syndromes (OPUS-TIMI 16) TrialCirculation, 2000
- Long-Term Treatment with a Platelet Glycoprotein-Receptor Antagonist after Percutaneous Coronary RevascularizationNew England Journal of Medicine, 2000
- Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudyThe American Journal of Cardiology, 2000
- Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: Bleeding, reversal, thrombocytopenia, and retreatmentAmerican Heart Journal, 2000
- Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopeniaThe American Journal of Cardiology, 1999
- Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 1998
- Effects of Platelet Glycoprotein IIb/IIIa Blockade With Tirofiban on Adverse Cardiac Events in Patients With Unstable Angina or Acute Myocardial Infarction Undergoing Coronary AngioplastyCirculation, 1997
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationNew England Journal of Medicine, 1997